Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avoralstat - BioCryst Pharmaceuticals

Next Previous
Search
Drug Profile

Avoralstat - BioCryst Pharmaceuticals

Alternative Names: BCX-4161

Latest Information Update: 06 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Developer BioCryst Pharmaceuticals; Clearside Biomedical
  • Class Anti-inflammatories; Carboxylic acids; Cyclopropanes; Eye disorder therapies; Pyridines; Small molecules
  • Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema
  • Discontinued Hereditary angioedema

Most Recent Events

  • 24 Feb 2025 BioCryst Pharmaceuticals plans a clinical trial for diabetic macular edema in 2025
  • 03 Jan 2024 Preclinical trials in Diabetic macular oedema in USA (PO) (Clearside Biomedical Pipeline, January 2024)
  • 03 Nov 2023 BioCryst Pharmaceuticals plans a preclinical trial for diabetic macular edema in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top